Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparison of New SUREcore Biopsy of Needle to Standard of Care During Transperineal Prostate Biopsies
Sponsor: University of California, Davis
Summary
To study a novel biopsy needle system for performing transperineal prostate biopsy. Prostate biopsy remains the standard approach for prostate cancer detection. While pre-biopsy MRI allows for targeting of visible lesions, systemic or 'off target' samples are recommended due to the well-recognized risk of undegrading and under sampling with current commercially available needles. The SureCore plus single-use biopsy needle produces a more intact tissue core with a same caliber 18g needle with \~21% more tissue per core in pre-clinical studies. This research study will determine if a new biopsy needle designed to produce more robust tissue cores per sample can improve detection and characterization of prostate cancer.
Official title: Comparison of BARD Max Core 18g Needle With Uro1 SUREcore 18g Needle in Targeted Prostate Biopsies
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-05-01
Completion Date
2027-12-01
Last Updated
2025-07-20
Healthy Volunteers
No
Conditions
Interventions
Comparison of Biopsy Needle Types for Prostate Biopsy
Each patient will undergo a standard of care prostate biopsy according to the clinical indication alternating between the SureCore and standard Bard needle
Locations (1)
UC Davis Departments of Urologic Oncology
Sacramento, California, United States